Pharma Doc
Contributor since: 2014
Latest Articles
CAR-T Developers Continue To Fly
Analyzing The CAR-T Market: What Companies Have Performed Best And Will The Trend Continue In 2018?
Why Is Gilead On Fire?
What AbbVie's Mavyret Approval Means To Gilead
Gilead's Multibillion-Dollar Earnings Gap: How Did It Happen, And What Will Boost The Stock Price?
Bristol Myers: Science Trumps The Headlines
The Biggest Microcap In My Biotech Portfolio With Fuel For Growth
Why Are Quality Biotech's Soaring?
Is The Biotech Decline A New Trend Or An Overreaction?
Gilead: Detailed Insight And Interpretation Behind The Headlines: Should You Be Scared?
If You Don't Have A Strategy Using The VXX In Your Portfolio, You're Crazy
Carnage In Biotech: What's Hot And What's Not
2 Lucrative Trades On Gilead That You Weren't Thinking About For 2016
The Takeaway From The AASLD Liver Meeting No One Is Talking About: Merck's Nuc Is A Long-Term Threat
What To Expect From Gilead's 2Q Earnings: The Theory Behind The Madness
How The Big Money Cashes In On Merck
Why Can't Gilead Run?
How To Manage The Risks To Investing In The Aging Population
All You Need To Know About HCV From The EASL Conference This Weekend
Biotech And Healthcare Investment: It's Not Your Father's Healthcare Sector Anymore
I Called It: What's The Take Home Message?
Is Merck Ready To Soar Or Flop? The Challenging Question Of Predicting Pipeline Potential
The Power Of Fear: Is Gilead A Buy Or Sell In 2015 After 1st Quarter Guidance?
What Lessons Has Express Scripts Taught Us? The Future For The Pharmaceutical Industry
How To Play Gilead In 2015: It's Going To Be A Bumpy Ride
Who Is The Devil? Will Gilead Fall Or Soar In 2015?
A Comprehensive Comparison Of Gilead's Harvoni And AbbVie's Triple HCV Regimen: What The HCV Marketplace May Look Like In 2015 And Beyond
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Why Did Gilead Drop Friday? Is It Justified Or Just An Overreaction?
Detailed Analysis Of Sarepta's Ebola Virus Cocktail: Full Phase I Clinical Trial Analysis For Non-Scientists
Gilead's Harvoni Will Dominate J&J's Olysio In HCV: Is Olysio Even Relevant Anymore?
Called Strike 3 For Bristol-Myers Squibb: What This Says For Gilead And Its Competitors In The Hep C Market